Navigation Links
Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth
Date:4/8/2009

ment of patients with non-Hodgkin's lymphoma. Micromet's second BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights to MT110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy and intended utilization of our product candidates and the developme
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
2. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
3. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
4. Genmab Announces HuMax-CD32b Pre-Clinical Program
5. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
6. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
7. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
8. CorMatrix Announces Pre-Clinical Data Suggesting Next Generation ECM Technology(TM) Can Improve Cardiac Function
9. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
10. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
11. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 China Cord Blood Corporation ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... a Hong Kong listed company ... into an agreement (the "Agreement") to purchase the Company,s ...
(Date:5/4/2015)... , May 4, 2015   Tocagen ... updated interim data from Tocagen,s ongoing investigational studies ... Symposium of the American Association of Neurological Surgeons ... held May 1-2, 2015, in Washington, ... company held a meeting with FDA and continues ...
(Date:5/4/2015)... 4, 2015   Sentrian ™, the Remote Patient ... with the Scripps Translational Science Institute (STSI) ... patients with chronic obstructive pulmonary disease (COPD), a chronic ... the nation,s third leading cause of death. The patients ... System , a wholly owned subsidiary of Anthem.   ...
(Date:5/1/2015)... Md. , May 1, 2015  Northwest Biotherapeutics ... company developing DCVax® personalized immune therapies for solid tumor ... the $28.5 million second tranche of a $40 million ... Woodford first invested $25 million in NW ... Woodford entered into an agreement with the Company for ...
Breaking Biology Technology:China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 2CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 3CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 4CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 5NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3
... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced today that ... for the brand name Ranexa(R) (ranolazine)., On July ... granted,marketing authorization for ranolazine in all 27 European Union ... approval for the Ranexa brand name in Europe provides,important ...
... Named as CEO ... COO, ALTAMONTE SPRINGS, Fla., Aug. 14 Milestone ... and commercialization of niche oncology products, today,announced the appointment ... 12, 2008. Current President, CEO and Co-founder, Frank,Jacobucci, will ...
... Bio-,Pharmaceutical Technology, Inc (OTC Bulletin Board: HFGB), a ... raw materials,for use in pharmaceutical, nutraceutical and food ... for the three and six month periods,ended June ... 2008, sales of our products increased,substantially. Revenue received ...
Cached Biology Technology:CV Therapeutics Receives European Approval for the Brand Name Ranexa(R) 2Milestone Biosciences, LLC Further Strengthens Executive Management Team 2Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008 2
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... Conn. , Apr. 1, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... of Wocket smart wallets is underway to early access ... access group includes usage at retail outlets including Walmart, ... Pharmacy. Users report Wocket was accepted at all outlets ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... Dr. Sarit Larisch, Head of the Cell Death Research Laboratory ... awarded the prestigious Johnson & Johnson Focused Funding grant for ... Parkinson,s disease. The award, which is granted each year to ... announced in 2008, and officially conferred earlier this month at ...
... thousands of years it has been prescribed by traditional healers in ... pain to fever and flu. , Now for the first time, ... pain relieving properties of Hyptis crenata otherwise known ... mice, the team led by researcher Graciela Rocha was able to ...
... The atomic-level action of a remarkable class of ... the Lawrence Berkeley National Laboratory (Berkeley Lab) using a ... (ALS). These protein motors play pivotal roles in gene ... of all biological cells, as well as infectious agents, ...
Cached Biology News:Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Got a pain? -- Have a cup of Brazilian mint 2Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4
Rabbit Anti-Ferret Whole Serum Antibody, Unconjugated...
... Molecular Imaging's proprietary Focus™ detector technology, while ... the R4. The microPET Focus 120 ... avaiable PET scanner. Focus scanners also ... scinitallor based PETsystems. The combination of ...
... pAcGHLT-A,B,C ... Vector Set,pAcGHLT-XylE ... Vector,Thrombin Powder,Thrombin ... Inhibitor Cocktail,Insect ...
... has been developed to significantly increase the ... Stability is increased at room temperature ... This product is subjected to 0.45 ... azide. This formulation insures consistently high ...
Biology Products: